A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
← catalyst calendarSponsored by Nektar Therapeutics (industry) · NKTR — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
396estimated
Sites
107
Countries
Australia, Bulgaria, Canada +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-15 | actual | When the study began enrolling |
| Primary completion | 2025-05-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate to Severe Atopic Dermatitis
Interventions
- Drug: Rezpegaldesleukin — also filed as NKTR-358, REZPEG, LY3471851 (formerly)
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16
measured Week 0 and Week 16
Permalink · NKTR's whole pipeline · Catalyst calendar · Every registered study · What changed